Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on July 7, 2023, covering the date of the earliest event reported on June 30, 2023. The filing discloses the entry into a material definitive agreement regarding the Company's manufacturing facilities.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a lease amendment. Specific financial terms disclosed include:
- Annual Base Rent (Aug 1, 2023 - Sep 30, 2023): $0
- Annual Base Rent (Oct 1, 2023 - Jul 31, 2024): Approximately $1.5 million
- Future Rent: Scheduled to increase annually after July 31, 2024.
Material Changes
The primary material change is the extension of the lease term for the Company's manufacturing space located at 36 Crosby Drive, Bedford, Massachusetts. The lease term, originally scheduled to expire on July 31, 2023, has been extended to July 31, 2028.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies beyond the standard incorporation of the lease amendment by reference. The agreement ensures continued occupancy of the manufacturing premises for five additional years.
Key Facts for Investor Verification
- Verify the specific annual rent increase percentages for the period following July 31, 2024, as the filing only states rent will "increase annually."
- Confirm the total square footage of the Premises to assess the cost per square foot relative to the $1.5 million annual rent.
- Review the full text of the Third Amendment (Exhibit 10.1) for any termination clauses, renewal options, or additional obligations not summarized in the 8-K.